Cell4Cure Consortium (C4C)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2012
  • Initiating Organization: CELLforCURE
  • Initiator Type: Industry
  • No disease focus
  • Location: Europe

Abstract

The CellforCURE (C4C) consortium aims to advance the current good manufacturing practice (cGMP) production of therapeutic cell therapies. The consortium is led by Cellectis, a biotech focused on the development of adoptive immunotherapies, and CELLforCURE, the largest commercial industrial facility for the production of therapeutic cell therapies in Europe. The consortium also includes seven public-sector organizations and university medical centers, who collaborate with the private-sector companies.

Mission

C4C aims to advance the cGMP production of therapeutic cell therapies. The consortium is led by Cellectis, a biotech focused on the development of adoptive immunotherapies, and CELLforCURE, the largest commercial industrial facility for the production of therapeutic cell therapies in Europe. The consortium also includes seven public-sector organizations and university medical centers, who collaborate with the private-sector companies.

Structure & Governance

C4C is coordinated by CELLforCURE, a subsidiary of the leading French biopharmaceutical company, LFB Biotechnologies. It also involves the participation of two biotech companies (Celogos and CleanCells) and seven public-sector organizations and university medical centers (APHP, Biological Resource Center at Lyon University Medical Center, Bordeaux University Medical Center, CHU de Toulouse, French Blood Agency, Lille University Medical Center/University of Lille 2, and Nantes University Medical Center).

Financing

C4C was established with an €80 million investment from the consortium members and €30 million from the French government as part of the “Investing in the Future” solicitation.  This solicitation aimed to stimulate industry-academic collaborations to advance the field of cell therapy research, development, and industrial production. 

Impact/Accomplishment

The first five products are currently being developed, with a view to validating the facility dedicated to the routine production of clinical trial and therapeutic batches. This facility is located on the LFB Group’s site in Les Ulis, close to Paris.

Points of Contact

Cellectis
Philippe Valachs
Company Secretary
phone: +33 (0)1 81 69 16 00 -
email: media@cellectis.com

LFB / CELLforCURE
Sandrine Charrieres
Corporate Communications LFB
phone: 01 69 82 72 80

FTI Consulting
Jeanne Bariller
Relations Presse
phone: 01 47 03 68 63
phone: 06 74 12 44 52

Sponsors & Partners

APHP                                                   

Bordeaux University Medical Center

Celegos

CHU de Toulouse

CleanCells

Establissement Francais du Sang, EFS

Lille University Medical Center/University of Lille

Lyon University Medical Center

Nantes University Medical Center


Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.